CGT

208개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved208 programs
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology and Blo…Phase 1

Autologous CAR123 T lymphocytes (Autologous CAR123 T lymphocytes)

Leukemia, Myeloid, Acute(AML); Precursor Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute(AML)

#LeukemiaMyeloidAcuteAML#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleMustang Bio, Inc.Phase 1

Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes)

Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19-targeting CAR T cells (Autologous CD19-targeting CAR T cells)

Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CD123 dual-target CAR-T module (Autologous CD33/CD123 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CLL1 dual-target CAR-T module (Autologous CD33/CLL1 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Autologous CD5 CAR T-cells (Autologous CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Autologous CD5.CAR/28zeta CAR T cells (Autologous CD5.CAR/28zeta CAR T cells)

T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Lymphoma

#T-cellAcuteLymphoblasticLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD5/CD7 dual-target CAR-T module (Autologous CD5/CD7 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Autologous CD7 CAR T-cell (Autologous CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleGuangzhou Bio-gene Technology C…Phase 1

BAFFR CAR-T (BAFFR CAR-T)

B Acute Lymphoblastic Leukemia/Lymphoma · B Acute Lymphoblastic Leukemia/Lymphoma

#BAcuteLymphoblasticLeukemiaLymph#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSheba Medical CenterPhase 3

CAR-T CD19 (CAR-T CD19)

Acute Myeloid Leukemia · CD19

#CD19#CGT#Phase3#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleHebei Taihe Chunyu Biotechnolog…Phase 2

CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） (CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）)

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL); AML (Acute Myelogenous Leukemia) · Lymphoma, B-cell, Aggressive Non-Hodgkin

#LymphomaB-cellAggressiveNon-Hodg#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleUniversity College, LondonPhase 1

CARCCR9 T cells (CARCCR9 T cells)

T Cell Acute Lymphoblastic Leukemia; T Cell Lymphoblastic Lymphoma · T Cell Acute Lymphoblastic Leukemia

#TCellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleZhujiang HospitalPreclinical

AML (CART therapy in Acute myeloid leukemia, CART therapy in Acute myeloid leukemia(AML))

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 2

CART-38 (CART-38)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleGyala TherapeuticsPhase 2

CART84 (CART84)

Acute Myeloblastic Leukaemia; Leukemia, T-Cell · Acute Myeloblastic Leukaemia

#AcuteMyeloblasticLeukaemia#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

CD117 CAR T-cells (CD117 CAR T-cells)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting

5 / 11 pages

← PreviousNext →